EFFECTIVENESS OF OLANZAPINE TREATMENT FOR SCHIZOPHRENIA- 12-MONTH RESULTS OF THE POST MARKETING SURVEILLANCE IN JAPAN
Author(s)
Naohiro Nakahara, BSc, Research Scientist1, Noriko Takagaki, BSc, Research Associate1, Shinji Fujikoshi, Bsc, Statistician1, Motoki Kuramochi, MD, PhD, Clinical Research Physician1, Isao Kamae, MD, PhD, Professor2, Michihiro Takahashi, MD, PhD, Lead Clinical Research Physician11Eli Lilly Japan K.K, Kobe, Japan; 2 Kobe University Graduate School of Medicine, Kobe, Japan
OBJECTIVES: To present the outcomes associated with olanzapine treatment of schizophrenia patients participating in the Olanzapine Post Marketing Surveillance in Japan (OPMS-J), and to compare the maintenance rate of olanzapine in the OPMS-J with that of typical and atypical antipsychotic medication in the Schizophrenia Outpatient Health Outcomes (SOHO) study. METHODS: The OPMS-J is 12-month, prospective, observational study of the health outcomes associated with olanzapine treatment in Japan. Patient enrollment started before November 2003, and completed by July 2004. A total of 1955 out/in-patients were enrolled in the OPMS-J, of whom 1849 were considered as qualified subjects for the analysis of effectiveness. Four types of outcomes were measured in the study: social activity (social activity was assessed using single-item questions that asked whether the patient was involved in any social interactions in the previous 4 weeks), EQ-5D, Clinical Global Impression-Schizophrenia scale (CGI-SCH) and the maintenance rate of olanzapine. Regarding the maintenance rate of olanzapine, the OPMS-J was compared with the SOHO study, as an external control, with typical and atypical antipsychotic medication including olanzapine. RESULTS: The three outcomes, i.e., social activity, EQ-5D and the CGI-SCH, all, significantly improved when the scores at the baseline were statistically compared with those at the endpoint of 12-month follow-up or the end of the surveillance (p<0.001). Also, the deterioration rate of patients status was observed as less than 5 % in the group measured with the CGI-SCH. The maintenance rate of olanzapine in the OPMS-J was 68.25 % (n=1262) in the 12-month follow-up duration, which is similar to that of SOHO study reported at the 12-month endpoint, ranging from 79.5% to 51.4%. CONCLUSION: The improvement of patient-reported outcomes with respect to olanzapine was confirmed in the OPMS-J, a post marketing surveillance in Japan. Also, the maintenance rate of olanzapine in Japan was similar as that in the European study.
Conference/Value in Health Info
2007-10, ISPOR Europe 2007, Dublin, Ireland
Value in Health, Vol. 10, No. 6 (November/December 2007)
Code
PMH3
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Mental Health